CD274 and non-small cell lung carcinoma: Among patients with NSCLC who had undergone whole-exome sequencing, the clinical use of TMB combined with PD-L1 expression had a higher value of prediction with PFS, complete response, partial response, or DCB than TMB or PD-L1 expression alone (1-year PFS: AUC, 0.829; 3-year PFS: AUC, 0.839; ORR: AUC, 0.803; DCB: AUC, 0.740) (Figure 3A and B; eFigure 22 in the Supplement).